PHARMACY

Impax launches generic Metadate CD

BY David Salazar
HAYWARD, Calif. — Impax Laboratories on Thursday announced the launch of its generic of Metadate CD (methylphenidate hydrochloride) extended-release capsules. 
 
Impax’s generic will be available in 10-, 20-, 30-, 40-, 50- and 60-mg dosage strengths. The drug had U.S. sales of about $151 million for the 12 months ended July 2016, according to IMS Health data. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Allergan, Adamas announce new Namzaric dosage strengths availability

BY David Salazar
DUBLIN and EMERYVILLE, Calif. —Allergan and Adamas Pharmaceuticals on Thursday announced the availability of all four dosage strengths of its Namzaric (memantine and donepezil hydrochloride) extended-release capsules. 
 
Namzaric is a fixed-dose combination of memantine and 10 mg donepezil hydrochloride indicated to treat moderate to severe Alzheimer’s disease in patients stabilized on 10 mg of donepezil hydrochloride. The Food and Drug Administration approved the drug in July. 
 
“We are excited that with the new available dosage strengths patients with moderate to severe Alzheimer's disease, who are currently stabilized on Aricept, donepezil hydrochloride (10 mg) can now start combination therapy directly with NAMZARIC,” Allergan chief medical officer Dr. Gavin Corcoran said. Namzaric offers these patients the benefits of combining two products that each work differently to treat moderate to severe Alzheimer's disease, without increasing the number of pills a patient and their caregiver need to administer each day.”
 
Namzaric will be commercially available in 30-count bottles of 7-, 10-, 14-, 21- and 28-mg memantine/10-mg donepezil hydrochloride dosage strengths. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Report: Opioid abuse cost burden exceeds $78 billion

BY DSN STAFF
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?